| Project/Area Number |
18K08197
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53040:Nephrology-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 慢性腎臓病 / 線維化 / microRNA / 血管周細胞 |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to explore the pathogenic mechanism and and new therapeutic targets of "Chronic kidney disease (CKD)", which is attracting attention as a new national disease. By focusing on the role of Dicer, which is an RNase that processes precursor of microRNAs, in PDGFRβ-positive cells and elucidating the mechanism of cytotoxicity in the progression of CKD, we searched for new biomarkers and new therapeutic targets. Studies using PDGFRβ-positive cell-specific Dicer-deficient mice revealed that the miR-9-5-p/Pdgfrb system is involved as a key target in the progression of renal interstitial fibrosis.
|
| Academic Significance and Societal Importance of the Research Achievements |
新たな国民病として注目されている「慢性腎臓病（Chronic kidney disease: CKD）」の新たな治療標的の候補因子が抽出されてきており、国民の健康寿命延伸、QOL維持向上に寄与し得る社会的意義の高い研究成果が得られている。
|
